Hepatitis C Medicaid Affinity Group:
Overview and Expression of Interest Form
Hepatitis C Medicaid Affinity Group Overview
The Hepatitis C Medicaid Affinity Group aims at increasing the number and percentage of
Medicaid patients diagnosed with hepatitis C virus (HCV) infection that are successfully treated
and cured. These outcomes have substantial benefits to the health and wellbeing of persons
living with HCV as well as significant social value including preventing transmission, early
mortality, productivity loss and substantial direct healthcare costs.
Participation in the Affinity Group is voluntary. The Office of HIV/AIDS and Infectious Disease
Policy (OHAIDP) in the Office of the Assistant Secretary for Health at Department of Health and
Human Services (HHS) will coordinate the HCV Medicaid Affinity Group in active collaboration
with CMS, CDC, and HRSA. Subject Matter Experts (SME) from collaborating federal partners
will support the Affinity Group by providing technical assistance, consultation, and feedback.
Benefits to State Participants:
Direct technical assistance that supports improved HCV-related outcomes among Medicaid
enrollees through better coordination, delivery, and assessment of high quality HCV prevention,
treatment and cure
Opportunity for states to learn and share best and promising approaches to improve health
outcomes and reduce costs by successfully treating and curing Medicaid enrollees diagnosed
with HCV
Stronger collaborative relationships among state Medicaid programs, and other state partners
(public or private) who are well positioned to advice and support efforts for maximum impact
The expectation is that the most viable and effective solutions and innovations will be
generated by states themselves while working collaboratively with their state colleagues as a
team, stakeholders in the state, and federal partners. Active participation in monthly Hepatitis